Pressure-overloaded myocardial
hypertrophy is an independent risk factor for various
cardiovascular diseases (CVDs), such as
heart failure (HF),
arrhythmia, and even
sudden death. It is reported that
QiShenYiQi pill (QSYQ) is widely used in the treatment of CVDs and can prevent pathological
hypertrophy of myocardium, but its specific mechanism is still unclear. In this study, a rat model of myocardial
hypertrophy was established through the pressure overload caused by abdominal aortic constriction in Wistar rats. The rats were randomly divided into model group,
valsartan group, and QSYQ group, and
sham-operated animals served as the control group. At the 4 and 8 weeks of intervention, the general morphology of the heart, myocardial
collagen content,
collagen volume factor (CVF),
collagen type I,
collagen type III, myocardial pathological changes, and the expression of
ANP, β-MHC, TGF-β1, and CTGF were analyzed, respectively, in order to explore the possible effect of QSYQ on the mechanism of myocardial
hypertrophy. We observed that QSYQ could effectively improve myocardial
hypertrophy in pressure-overloaded rats, which was related to the regulatory mechanism of TGF-β1 and CTGF.